Sunshine Biopharma (SBFM)

May 15, 2025, 4:15 PM EDT - 21 days ago

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

May 6, 2025, 8:30 AM EDT - 4 weeks ago

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

Apr 21, 2025, 8:30 AM EDT - 6 weeks ago

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

Apr 3, 2025, 10:50 AM EDT - 2 months ago

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Apr 2, 2025, 1:20 PM EDT - 2 months ago

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Apr 2, 2025, 11:35 AM EDT - 2 months ago

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Apr 2, 2025, 8:00 AM EDT - 2 months ago

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Apr 1, 2025, 5:09 PM EDT - 2 months ago

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Mar 24, 2025, 8:00 AM EDT - 2 months ago

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Mar 10, 2025, 9:00 AM EDT - 3 months ago

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Jan 21, 2025, 8:00 AM EST - 4 months ago

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Jan 15, 2025, 8:00 AM EST - 5 months ago

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Dec 9, 2024, 7:30 AM EST - 6 months ago

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Dec 4, 2024, 4:05 PM EST - 6 months ago

Sunshine Biopharma Launches a New Generic Prescription Drug

Dec 2, 2024, 8:00 AM EST - 6 months ago

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Nov 6, 2024, 8:00 AM EST - 7 months ago

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Sep 26, 2024, 8:00 AM EDT - 9 months ago

Sunshine Biopharma Launches Two New Generic Prescription Drugs

Sep 4, 2024, 8:00 AM EDT - 9 months ago

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Aug 26, 2024, 8:00 AM EDT - 10 months ago

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

Aug 19, 2024, 8:00 AM EDT - 10 months ago

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

Aug 6, 2024, 8:00 AM EDT - 10 months ago

Sunshine Biopharma Announces Reverse Stock Split

Apr 19, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Feb 15, 2024, 9:15 AM EST - 1 year ago

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Feb 13, 2024, 9:00 AM EST - 1 year ago

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Dec 4, 2023, 8:30 AM EST - 1 year ago

Sunshine Biopharma Moves Principal Office to New York City

Nov 13, 2023, 8:30 AM EST - 1 year ago

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

Sep 21, 2023, 9:05 PM EDT - 1 year ago

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

Aug 11, 2023, 8:30 AM EDT - 1 year ago

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

May 16, 2023, 2:15 PM EDT - 2 years ago

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

May 16, 2023, 9:58 AM EDT - 2 years ago

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

May 12, 2023, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

May 11, 2023, 9:00 AM EDT - 2 years ago

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

Apr 5, 2023, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Feb 28, 2023, 7:30 AM EST - 2 years ago

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

Feb 10, 2023, 7:35 AM EST - 2 years ago

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Jan 19, 2023, 7:30 AM EST - 2 years ago

Sunshine Biopharma Announces Share Repurchase Program

Dec 20, 2022, 8:00 AM EST - 2 years ago

Sunshine Biopharma's Annual Letter to Shareholders

Dec 5, 2022, 5:46 PM EST - 2 years ago

4 Stocks Meeting GuruFocus' Value Screens in December

RM CACC WFG

Nov 16, 2022, 8:00 AM EST - 2 years ago

Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project

Oct 20, 2022, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue

Aug 4, 2022, 8:00 AM EDT - 3 years ago

Sunshine Biopharma Files Its Second Quarter Report With the SEC

Jul 28, 2022, 8:10 AM EDT - 3 years ago

Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona

May 9, 2022, 11:03 AM EDT - 3 years ago

Sunshine Biopharma: An Opportunity Knocking?

Apr 28, 2022, 4:50 PM EDT - 3 years ago

Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market

Apr 28, 2022, 9:20 AM EDT - 3 years ago

Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ: SBFM)

Apr 26, 2022, 12:41 AM EDT - 3 years ago

Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market

Apr 25, 2022, 10:57 AM EDT - 3 years ago

Why Sunshine Biopharma Stock Is Surging

Apr 25, 2022, 8:00 AM EDT - 3 years ago

Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells

Apr 19, 2022, 6:01 PM EDT - 3 years ago

5 Stocks Halted In Tuesday's Session

LGHL